The Wellcome Genome Campus is a scientific research campus built in the grounds of Hinxton Hall, Hinxton in Cambridgeshire, England.
Annotation of biomedical entities with widely used, well-structured ontologies and ontology-aware tools ensures data and analyses are Findable, Accessible, Interoperable, and Reusable (FAIR). Standardized terms with synonyms support lexical search, while ontology structure enables biologically meaningful grouping of annotations, such as by location and type. However, ontologies serving diverse communities are often more complex than needed for specific applications, creating barriers to adoption by researchers and resource developers. For example, cell atlases often attempt simplifications by manually building term hierarchies linking to cell type and anatomy ontologies, but these may include relationship types unsuitable for grouping annotations. We present tools for validating human expert curated term hierarchies, developed in two human reference atlas projects, against ontology structures. The tools provide tabular statistics plus graphical views of matching and non-matching terms and relationships to support discussion and conflict resolution. The HuBMAP Human Reference Atlas (HRA) effort is used to validate the approach and tools, and the Human Developmental Cell Atlas is featured as a use case.
Dictyostelids are a species-rich clade of cellular slime molds that are widely found in soils and have been studied for over a century. Due to a lack of genome editing methods, most molecular research in Dictyostelids has focused on only a single species, Dictyostelium discoideum, which has severely limited broad-scale comparative analyses. Here, we introduce the first CRISPR-Cas9 editing approach that is cloning-free, selection-free, highly efficient, and effective across Dictyostelid species that diverged millions of years ago. Depending on the CRISPR-Cas9 target site, our editing approach generates knock-out efficiencies of up to 90% and knock-in efficiencies of up to 50% without a selective marker. We show that mutants can be isolated as soon as one day post-transfection, vastly outpacing existing methods for generating knock-outs, fusion proteins, and expression reporters. Leveraging single-cell sorting and fluorescent microscopy, we could readily apply our CRISPR-Cas9 editing approach to phylogenetically distant Dictyostelid species, including those that have never been genome edited before. Our methods therefore open the door to performing broad-scale genetic interrogations across the Dictyostelids.
Abstract T cell receptor (TCR) affinity enhancement can introduce off-target cross-reactivity with life-threatening consequences, as illustrated by the MAGE-A3-specific A3A TCR, which caused fatal cardiotoxicity through recognition of a Titin-derived peptide. Here, we reconstructed the cross-reactivity landscape by reverse-engineering A3A toward its wild-type precursor, generating intermediate variants in which engineered CDR2α residues are systematically reverted to the wild-type sequence. Reverting just two engineered residues yields a receptor, v9, that retains MAGE-A3 cytotoxicity comparable to A3A while eliminating Titin and other acquired cross-reactivities. Structurally, these substitutions reduce CDR2α-MHC contacts and disrupt an intra-TCR CDR2α-CDR3β interaction, propagating conformational changes across CDR3 loops that reshape peptide engagement without altering docking geometry. These results demonstrate that mutations outside the peptide-contacting CDR3 loops can allosterically reconfigure antigen specificity and establish simple stepwise reverse engineering to wild-type as a strategy for correcting TCR cross-reactivity.
Chemical probes are indispensable tools for validating therapeutic hypotheses, yet their broader impact on early-stage drug discovery remains unquantified. To our knowledge, this study represents the first systematic, large-scale investigation of the chemical probe literature. By screening over 18 million articles using a high-quality dictionary of 561 chemical probes, we identified 20,000 articles mentioning a chemical probe which resulted in 5,558 unique target-disease (T-D) associations. Our analysis yields four principal findings that redefine the utility of these chemicals: First, we show that chemical probe evidence typically precedes the appearance of structured data in major knowledge bases by 1–7 years, providing a crucial lead time for target prioritisation. Second, we identified 353 T-D pairs (6.4%) with no prior evidence in the Open Targets Platform, highlighting the approach’s discovery potential. Third, the application of strict novelty filters uncovered 135 new high-confidence associations between targets and diseases, revealing distinct opportunities for therapeutic repurposing in non-oncological, rare autoimmune diseases, and diseases without effective therapies due to complex biology or high treatment resistance. Finally, we demonstrate that chemical probes are essential for strengthening evidence, providing functional validation for associations previously supported only by weaker, correlative data such as RNA expression or animal models. Collectively, these findings illustrate that chemical probes catalyse early therapeutic discovery, emphasising the importance of cataloguing existing probes and identifying new ones.
